Gareth Thomas BDS, MScD, PhD, FDSRCS, FRCPath

University Hospital Southampton NHS Foundation Trust.

Professor Gareth Thomas is Chair of Experimental Pathology at the University of Southampton. His laboratory focuses on the role of the tumour microenvironment in promoting tumour progression, investigating the interactions between different cell types. The work has a strong translational component, identifying potential prognostic/predictive biomarkers, therapeutic targets and molecular classifiers in cancer tissues, including the characterisation of cancer-associated fibroblasts and intratumoral immune cells, and development of immunotherapy clinical trials in squamous carcinoma of the head and neck.

dont miss

Targeted therapies: aiming at the tumour micro-environment

While immune checkpoint inhibitors such as -PD1, have shown efficacy across cancer types, most patients (~80%) fail to respond. Currently, it is unclear how to select patients most likely to benefit, or how to combine the expanding number of immunotherapies in development.

Our aim is to develop immune stratification for cancer patients; using NGS, bioinformatic analyses and in vivo modelling, we have characterised the molecular heterogeneity of tumour phenotypes; characterising prognostic/predictive lymphocyte signatures and identifying targetable immune evasion mechanisms. The seminar will discuss the potential for immune-based classification of cancers.

EVEN MORE SEMINARS

  • Mavis Nye BCaH: Speaking at the Oncology Convention

    Mavis Nye BCaH
    Mavis Nye Foundation

    Mesothelioma

  • Merina Ahmed: Speaking at the Oncology Convention

    Merina Ahmed
    Royal Marsden NHS foundation Trust

    Stereotactic Radiotherapy for lung tumours and oligometastatic disease

  • Cheng Boon: Speaking at the Oncology Convention

    Cheng Boon
    Worcestershire Royal Hospital

    Consultant Clinical Oncologist, GI and Head & Neck

  • Dr Ioanna Nixon: Speaking at the Oncology Convention

    Dr Ioanna Nixon
    Beatson West of Scotland Cancer center, NHS Greater Glasgow and Clyde

    When the oncologist meets the patient: value of compassion. How well are we doing?

  • Michael Schreiber: Speaking at the Oncology Convention

    Michael Schreiber
    Brain Tumor Foundation, Chairman

    Brain Tumors - Innovation, support and advocacy